Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis
IJC Heart & Vasculature · 2023-08 · 47 · 101246
DOI: 10.1016/j.ijcha.2023.101246 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IJC Heart & Vasculature, 2023-08. Verfasst von Elinor Tan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, The Royal Melbourne Hospital, Melbourne, Australia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Tissue necrosis releases cell-free deoxyribonucleic acid (cfDNA), leading to rapid increases in plasma concentration with clearance independent of kidney function.
Aim
To explore the diagnostic role of cfDNA in acute myocardial infarction (AMI).
Methods
This systematic review and meta-analysis included studies of cfDNA in patients with AMI and a comparator group without AMI. The quality assessment of diagnostic accuracy studies-2 (QUADAS-2) tool was used, with AMI determined from the criteria of the original study. Standardised mean differences (SMD) were obtained using a random-effects inverse variance model. Heterogeneity was reported as I2. Pooled sensitivity and specificity were computed using a bivariate model. The area under the curve (AUC) was estimated from a hierarchical summary receiver operating characteristics curve.
Results
Seventeen studies were identified involving 1804 patients (n = 819 in the AMI group, n = 985 in the comparator group). Circulating cfDNA concentrations were greater in the AMI group (SMD 3.47 (95%CI: 2.54-4.41, p < 0.001)). The studies were of variable methodological quality with substantial heterogeneity (I2 = 98%, p < 0.001), possibly due to the differences in cfDNA quantification methodologies (Chi2 25.16, p < 0.001, I2 = 92%). Diagnostic accuracy was determined using six studies (n = 804), which yielded a sensitivity of 87% (95%CI: 72%-95%) and specificity of 96% (95%CI: 92%-98%). The AUC was 0.96 (95%CI: 0.93-0.98). Two studies reported a relationship between peak cfDNA and peak troponin. No studies reported data for patients with pre-existing kidney impairment.
Conclusion
Plasma cfDNA appears to be a reliable biomarker of myocardial injury. Inferences from existing results are limited owing to methodology heterogeneity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intensive Care Unit, The Royal Melbourne Hospital, Melbourne, Australia.
- Department of Anesthesiology, The Royal Melbourne Hospital, Melbourne, Australia.
- Department of General Medicine, The Royal Melbourne Hospital, Melbourne, Australia.
- Department of Surgery, The University of Melbourne, Melbourne, Australia.
- Department of Cardiology, Changi General Hospital, Singapore.
- Department of Cardiology, The Royal Melbourne Hospital, Melbourne, Australia.
Zitieren
APA
Tan, E., Liu, D., Perry, L., Zhu, J., Cid-Serra, X., Deane, A., Yeo, C., & Ajani, A. (2023). Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis. IJC Heart & Vasculature, 47, 101246. https://doi.org/10.1016/j.ijcha.2023.101246
Vancouver
Tan E, Liu D, Perry L, Zhu J, Cid-Serra X, Deane A, et al. Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis. IJC Heart & Vasculature. 2023;47:101246. doi:10.1016/j.ijcha.2023.101246
BibTeX
@article{Tan2023,
author = {Tan, Elinor and Liu, Daniel and Perry, Luke and Zhu, John and Cid-Serra, Ximena and Deane, Adam and Yeo, Colin and Ajani, Andrew},
title = {Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis},
journal = {IJC Heart & Vasculature},
year = {2023},
volume = {47},
pages = {101246},
doi = {10.1016/j.ijcha.2023.101246}
}
EUVIMED